This study aimed to assess the prevalence of diminished HER2 expression in breast cancer and to compare the prognostic outcomes among patients with HER2-low and HER2-negative breast cancer categorized based on hormone receptor (HR) status. This evidence concerns the gene ERBB2 and breast carcinoma.